RNA-Seq Data Analysis of Scots Pine (Pinus Sylvestris) Seedlings Subjected to A
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Literature Review Zero Alcohol Red Wine
A 1876 LI A A U R S T T S R U A L A I A FLAVOURS, FRAGRANCES AND INGREDIENTS 6 1 7 8 7 8 1 6 A I B A L U A S R T B Essential Oils, Botanical Extracts, Cold Pressed Oils, BOTANICAL Infused Oils, Powders, Flours, Fermentations INNOVATIONS LITERATURE REVIEW HEALTH BENEFITS RED WINE ZERO ALCOHOL RED WINE RED WINE EXTRACT POWDER www.botanicalinnovations.com.au EXECUTIVE SUMMARY The term FRENCH PARADOX is used to describe the relatively low incidence of cardiovascular disease in the French population despite the high consumption of red wine. Over the past 27 years numerous clinical studies have found a linkages with the ANTIOXIDANTS in particular, the POLYPHENOLS, RESVERATROL, CATECHINS, QUERCERTIN and ANTHOCYANDINS in red wine and reduced incidences of cardiovascular disease. However, the alcohol in wine limits the benefits of wine. Studies have shown that zero alcohol red wine and red wine extract which contain the same ANTIOXIDANTS including POLYPHENOLS, RESVERATROL, CATECHINS, QUERCERTIN and ANTHOCYANDINS has the same is not more positive health benefits. The following literature review details some of the most recent positive health benefits derived from the ANTIOXIDANTS found in red wine POLYPHENOLS: RESVERATROL, CATECHINS, QUERCERTIN and ANTHOCYANDINS. The positive polyphenolic antioxidant effects of the polyphenols in red wine include: • Cardio Vascular Health Benefits • Increase antioxidants in the cardiovascular system • Assisting blood glucose control • Skin health • Bone Health • Memory • Liking blood and brain health • Benefits -
12) United States Patent (10
US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S. -
(12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano Et Al
US 20090269772A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano et al. (43) Pub. Date: Oct. 29, 2009 (54) SYSTEMS AND METHODS FOR Publication Classification IDENTIFYING COMBINATIONS OF (51) Int. Cl. COMPOUNDS OF THERAPEUTIC INTEREST CI2O I/68 (2006.01) CI2O 1/02 (2006.01) (76) Inventors: Andrea Califano, New York, NY G06N 5/02 (2006.01) (US); Riccardo Dalla-Favera, New (52) U.S. Cl. ........... 435/6: 435/29: 706/54; 707/E17.014 York, NY (US); Owen A. (57) ABSTRACT O'Connor, New York, NY (US) Systems, methods, and apparatus for searching for a combi nation of compounds of therapeutic interest are provided. Correspondence Address: Cell-based assays are performed, each cell-based assay JONES DAY exposing a different sample of cells to a different compound 222 EAST 41ST ST in a plurality of compounds. From the cell-based assays, a NEW YORK, NY 10017 (US) Subset of the tested compounds is selected. For each respec tive compound in the Subset, a molecular abundance profile from cells exposed to the respective compound is measured. (21) Appl. No.: 12/432,579 Targets of transcription factors and post-translational modu lators of transcription factor activity are inferred from the (22) Filed: Apr. 29, 2009 molecular abundance profile data using information theoretic measures. This data is used to construct an interaction net Related U.S. Application Data work. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the (60) Provisional application No. 61/048.875, filed on Apr. -
Exploring Plant Stilbenes for Healthy Skin
Exploring Plant Stilbenes For Healthy Skin A thesis submitted to the University of East Anglia for the degree of Doctor of Philosophy By Erica Hawkins John Innes Centre Norwich September 2018 © This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with the author and that use of any information derived therefrom must be in accordance with current UK Copyright Law. In addition, any quotation or extract must include full attribution Abstract Accumulating evidence supports pharmacological roles for the plant stilbene, resveratrol in aging and disease contexts. Pterostilbene, a derivative of resveratrol, has been shown to have higher bioavailability and bio-efficacy than resveratrol, but is not abundant in natural sources. Previous work demonstrated that expression of the stilbene synthase gene, isolated from grapevine Vitis vinifera, under the control of a plant-wide promoter, led to a variety of growth and fertility problems in the transformed plants. To circumvent this problem two transgenic tomato lines were developed in this thesis to produce resveratrol and pterostilbene specifically in the fruit of tomato. An ex vivo full thickness human skin explant model was used to investigate the biological effects of aqueous tomato juices on normal human skin, and in an inflammatory disease-like context by treatment with inflammatory cytokines. Microarray analysis and qRT-PCR validation identified the differential regulation of several genes in human skin with tomato juice treatment, including a significant downregulation in expression of the aging-associated matrix metalloproteinase, MMP-12, observed with both wild type and resveratrol-enriched tomato extracts. -
All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA -
Polyamine Metabolism of Scots Pine Under Abiotic Stress
A 662 OULU 2015 A 662 UNIVERSITY OF OULU P.O. Box 8000 FI-90014 UNIVERSITY OF OULU FINLAND ACTA UNIVERSITATISUNIVERSITATIS OULUENSISOULUENSIS ACTA UNIVERSITATIS OULUENSIS ACTAACTA SCIENTIAESCIENTIAEA A RERUMRERUM Riina Muilu-Mäkelä NATURALIUMNATURALIUM Riina Muilu-Mäkelä Professor Esa Hohtola POLYAMINE METABOLISM OF University Lecturer Santeri Palviainen SCOTS PINE UNDER ABIOTIC Postdoctoral research fellow Sanna Taskila STRESS Professor Olli Vuolteenaho University Lecturer Veli-Matti Ulvinen Director Sinikka Eskelinen Professor Jari Juga University Lecturer Anu Soikkeli Professor Olli Vuolteenaho UNIVERSITY OF OULU GRADUATE SCHOOL; UNIVERSITY OF OULU, FACULTY OF SCIENCE; Publications Editor Kirsti Nurkkala NATURAL RESOURCES INSTITUTE FINLAND (LUKE), PARKANO RESEARCH UNIT ISBN 978-952-62-1057-5 (Paperback) ISBN 978-952-62-1058-2 (PDF) ISSN 0355-3191 (Print) ISSN 1796-220X (Online) ACTA UNIVERSITATIS OULUENSIS A Scientiae Rerum Naturalium 662 RIINA MUILU-MÄKELÄ POLYAMINE METABOLISM OF SCOTS PINE UNDER ABIOTIC STRESS Academic dissertation to be presented with the assent of the Doctoral Training Committee of Health and Biosciences of the University of Oulu for public defence in Kaljusensali (KTK112), Linnanmaa, on 11 December 2015, at 13 p.m. UNIVERSITY OF OULU, OULU 2015 Copyright © 2015 Acta Univ. Oul. A 662, 2015 Supervised by Professor Hely Häggman Docent Tytti Sarjala Reviewed by Doctor Sergio Ochatt Professor C. Peter Constabel ISBN 978-952-62-1057-5 (Paperback) ISBN 978-952-62-1058-2 (PDF) ISSN 0355-3191 (Printed) ISSN 1796-220X (Online) Cover Design Raimo Ahonen JUVENES PRINT TAMPERE 2015 Muilu-Mäkelä, Riina, Polyamine metabolism of Scots pine under abiotic stress. University of Oulu Graduate School; University of Oulu, Faculty of Science; Natural Resources Institute Finland (Luke), Parkano Research Unit Acta Univ. -
Preclinical and Clinical Studies
ANTICANCER RESEARCH 24: 2783-2840 (2004) Review Role of Resveratrol in Prevention and Therapy of Cancer: Preclinical and Clinical Studies BHARAT B. AGGARWAL1, ANJANA BHARDWAJ1, RISHI S. AGGARWAL1, NAVINDRA P. SEERAM2, SHISHIR SHISHODIA1 and YASUNARI TAKADA1 1Cytokine Research Laboratory, Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, Box 143, 1515 Holcombe Boulevard, Houston, Texas 77030; 2UCLA Center for Human Nutrition, David Geffen School of Medicine, 900 Veteran Avenue, Los Angeles, CA 90095-1742, U.S.A. Abstract. Resveratrol, trans-3,5,4'-trihydroxystilbene, was first and cervical carcinoma. The growth-inhibitory effects of isolated in 1940 as a constituent of the roots of white hellebore resveratrol are mediated through cell-cycle arrest; up- (Veratrum grandiflorum O. Loes), but has since been found regulation of p21Cip1/WAF1, p53 and Bax; down-regulation of in various plants, including grapes, berries and peanuts. survivin, cyclin D1, cyclin E, Bcl-2, Bcl-xL and cIAPs; and Besides cardioprotective effects, resveratrol exhibits anticancer activation of caspases. Resveratrol has been shown to suppress properties, as suggested by its ability to suppress proliferation the activation of several transcription factors, including NF- of a wide variety of tumor cells, including lymphoid and Î B, AP-1 and Egr-1; to inhibit protein kinases including IÎ B· myeloid cancers; multiple myeloma; cancers of the breast, kinase, JNK, MAPK, Akt, PKC, PKD and casein kinase II; prostate, stomach, colon, pancreas, and thyroid; melanoma; and to down-regulate products of genes such as COX-2, head and neck squamous cell carcinoma; ovarian carcinoma; 5-LOX, VEGF, IL-1, IL-6, IL-8, AR and PSA. -
(12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur Et Al
US 20150240226A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur et al. (43) Pub. Date: Aug. 27, 2015 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/16 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/02 (2006.01) CI2N 9/78 (2006.01) (71) Applicant: BP Corporation North America Inc., CI2N 9/12 (2006.01) Naperville, IL (US) CI2N 9/24 (2006.01) CI2O 1/02 (2006.01) (72) Inventors: Eric J. Mathur, San Diego, CA (US); CI2N 9/42 (2006.01) Cathy Chang, San Marcos, CA (US) (52) U.S. Cl. CPC. CI2N 9/88 (2013.01); C12O 1/02 (2013.01); (21) Appl. No.: 14/630,006 CI2O I/04 (2013.01): CI2N 9/80 (2013.01); CI2N 9/241.1 (2013.01); C12N 9/0065 (22) Filed: Feb. 24, 2015 (2013.01); C12N 9/2437 (2013.01); C12N 9/14 Related U.S. Application Data (2013.01); C12N 9/16 (2013.01); C12N 9/0061 (2013.01); C12N 9/78 (2013.01); C12N 9/0071 (62) Division of application No. 13/400,365, filed on Feb. (2013.01); C12N 9/1241 (2013.01): CI2N 20, 2012, now Pat. No. 8,962,800, which is a division 9/2482 (2013.01); C07K 2/00 (2013.01); C12Y of application No. 1 1/817,403, filed on May 7, 2008, 305/01004 (2013.01); C12Y 1 1 1/01016 now Pat. No. 8,119,385, filed as application No. PCT/ (2013.01); C12Y302/01004 (2013.01); C12Y US2006/007642 on Mar. 3, 2006. -
Atelier De Réflexion Prospective Vega Quels Vegétaux Et Systèmes De
Atelier de Réflexion Prospective VegA Quels VEGétaux et systèmes de production durAbles pour satisfaire les besoins en bioénergies, synthons et matériaux biosourcés ? Synthèse Générale 1 Editeurs Attention chacun doit avoir validé le document Paul COLONNA Directeur Scientifique Adjoint Alimentation et Bioéconomie INRA, UAR 0233 CODIR Collège de Direction 147 rue de l’Université, 75338 Paris cedex 07 Agnès KAMMOUN INRA Rue de la Géraudière BP 71627, 44316 Nantes cedex 03 Xavier MONTAGNE IFPEN Direction scientifique 1 et 4 avenue du Bois Préau - BP 311 92852 Rueil-Malmaison Cedex, France Christian SALES CIRAD Avenue Agropolis, 34398 Montpellier Cedex 5 Avec la contribution de Patricia Lefer pour la mise en page de ce document. Pour citer ce document COLONNA P., KAMMOUN A., MONTAGNE X., SALES C. (Editeurs). 2013 . Quels VEGétaux et systèmes de production durAbles pour satisfaire les besoins en bioénergie, synthons et matériaux biosourcés ? Rapport CIRAD – IFPEN – INRA (France), ?? p. N° ISBN ?? Le rapport est disponible en ligne sur le site de l’INRA : http://www.inra.fr/??? sur le site de l’IFPen ??? sur le site du CIRAD ??? 2 SOMMAIRE Introduction 9 Contributeurs 9 1. Résumé 12 2. Objectifs 13 3. Expression des besoins 19 3.1. Attentes et besoins en énergie, synthons et en matériaux biosourcés 19 3.1.1. Energies 20 3.1.1.1. Combustibles 21 3.1.1.2. Biocarburants 23 3.1.1.2.1. Transformation en gaz de synthèse 23 3.1.1.2.2. Le traitement du gaz de synthèse 24 3.1.2. Chimie et synthons 27 3.1.3. Matériaux 30 3.1.3.1. -
Springer Handbook of Enzymes
Dietmar Schomburg Ida Schomburg (Eds.) Springer Handbook of Enzymes Alphabetical Name Index 1 23 © Springer-Verlag Berlin Heidelberg New York 2010 This work is subject to copyright. All rights reserved, whether in whole or part of the material con- cerned, specifically the right of translation, printing and reprinting, reproduction and storage in data- bases. The publisher cannot assume any legal responsibility for given data. Commercial distribution is only permitted with the publishers written consent. Springer Handbook of Enzymes, Vols. 1–39 + Supplements 1–7, Name Index 2.4.1.60 abequosyltransferase, Vol. 31, p. 468 2.7.1.157 N-acetylgalactosamine kinase, Vol. S2, p. 268 4.2.3.18 abietadiene synthase, Vol. S7,p.276 3.1.6.12 N-acetylgalactosamine-4-sulfatase, Vol. 11, p. 300 1.14.13.93 (+)-abscisic acid 8’-hydroxylase, Vol. S1, p. 602 3.1.6.4 N-acetylgalactosamine-6-sulfatase, Vol. 11, p. 267 1.2.3.14 abscisic-aldehyde oxidase, Vol. S1, p. 176 3.2.1.49 a-N-acetylgalactosaminidase, Vol. 13,p.10 1.2.1.10 acetaldehyde dehydrogenase (acetylating), Vol. 20, 3.2.1.53 b-N-acetylgalactosaminidase, Vol. 13,p.91 p. 115 2.4.99.3 a-N-acetylgalactosaminide a-2,6-sialyltransferase, 3.5.1.63 4-acetamidobutyrate deacetylase, Vol. 14,p.528 Vol. 33,p.335 3.5.1.51 4-acetamidobutyryl-CoA deacetylase, Vol. 14, 2.4.1.147 acetylgalactosaminyl-O-glycosyl-glycoprotein b- p. 482 1,3-N-acetylglucosaminyltransferase, Vol. 32, 3.5.1.29 2-(acetamidomethylene)succinate hydrolase, p. 287 Vol. -
Polyketide Synthases in Cannabis Sativa L Flores-Sanchez, I.J
Polyketide synthases in Cannabis sativa L Flores-Sanchez, I.J. Citation Flores-Sanchez, I. J. (2008, October 29). Polyketide synthases in Cannabis sativa L. Retrieved from https://hdl.handle.net/1887/13206 Version: Corrected Publisher’s Version Licence agreement concerning inclusion of doctoral thesis in the License: Institutional Repository of the University of Leiden Downloaded from: https://hdl.handle.net/1887/13206 Note: To cite this publication please use the final published version (if applicable). Polyketide synthases in Cannabis sativa L. Isvett Josefina Flores Sanchez Isvett Josefina Flores Sanchez Polyketide synthases in Cannabis sativa L. ISBN 978-90-9023446-5 Printed by PrintPartners Ipskamp B.V., Amsterdam, The Netherlands Cover photographs: Cannabis sativa, “Skunk” pistillate floral clusters (1, 4, 10, 14); “Skunk” leaf (2, 7); “Skunk” young leaves (9); “Skunk” seed and calyx (3, 18); “Kompolti” flowers (6, 11, 13, 16); “Skunk” seeded calyxes (8); “Kompolti” leaves (5, 12, 15); “Kompolti” staminate floral clusters (19); “Skunk” seeds (17); “Kompolti” seeds (21); “Skunk” and “Kompolti” seeds (20); “Kompolti” pistillate floral clusters (22). Photograph: Isvett J. Flores-Sanchez Polyketide Synthases in Cannabis sativa L. Proefschrift Ter verkrijging van de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof. mr. P. F. van der Heijden, volgens besluit van het College voor Promoties te verdedigen op woensdag 29 october 2008 klokke 11.15 uur door Isvett Josefina Flores Sanchez Geboren te Pachuca de Soto, Hidalgo, Mexico in 1971 Promotiecommissie Promotor Prof. dr. R. Verpoorte Co-promotor Dr. H. J. M. Linthorst Referent Prof. dr. O. Kayser (University of Groningen) Overige leden Prof. -
The Regulation of NFE2L2 (NRF2) Signalling and Epithelial-To-Mesenchymal Transition in Age-Related Macular Degeneration Pathology
International Journal of Molecular Sciences Review The Regulation of NFE2L2 (NRF2) Signalling and Epithelial-to-Mesenchymal Transition in Age-Related Macular Degeneration Pathology Juha M. T. Hyttinen 1,*, Ram Kannan 2, Szabolcs Felszeghy 3,4, Minna Niittykoski 5, Antero Salminen 6 and Kai Kaarniranta 1,7 1 Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland; Kai.Kaarniranta@uef.fi 2 The Stephen J. Ryan Initiative for Macular Research (RIMR), Doheny Eye Institute, DVRC 203, 1355 San Pablo Street, Los Angeles, CA 90033, USA; [email protected] 3 Institute of Biomedicine, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland; Szabolcs.Felszeghy@uef.fi 4 Institute of Dentistry, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland 5 A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland; Minna.Niittykoski@uef.fi 6 Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland; Antero.Salminen@uef.fi 7 Department of Ophthalmology, Kuopio University Hospital, P.O. Box 100, 70029 KYS Kuopio, Finland * Correspondence: Juha.Hyttinen@uef.fi Received: 1 October 2019; Accepted: 14 November 2019; Published: 18 November 2019 Abstract: Age-related macular degeneration (AMD) is a mounting cause of loss of sight in the elderly in the developed countries, a trend enhanced by the continual ageing of the population. AMD is a multifactorial and only partly understood, malady. Unfortunately, there is no effective treatment for most AMD patients.